Literature DB >> 29318966

Chronic Inflammatory Diseases and Atherosclerotic Cardiovascular Disease: Innocent Bystanders or Partners in Crime?

Peter Riis Hansen1.   

Abstract

Inflammation plays a significant role in atherosclerosis and cardiovascular disease (CVD). Patients with chronic inflammatory diseases are at increased risk of CVD, but it is debated whether this association is causal or dependent on shared risk factors, other exposures, genes, and/or inflammatory pathways. The current review summarizes epidemiological, clinical, and experimental data supporting the role of shared inflammatory mechanisms between atherosclerotic CVD and rheumatoid arthritis, psoriasis, inflammatory bowel disease, and periodontitis, respectively, and provides insights to future prospects in this area of research. Awareness of the role of inflammation in CVD in patients with chronic inflammatory diseases and the potential for anti-inflammatory therapy, e.g., with tumor necrosis factor-α inhibitors, to also reduce atherosclerotic CVD has evolved into guideline- based recommendations. These include regular CVD risk assessment, aggressive treatment of traditional CVD risk factors, and recognition of reduced CVD as an added benefit of strict inflammatory disease control. At present, chronic inflammatory diseases would appear to qualify as partners in crime and not merely innocent bystanders to CVD. However, definite incremental contributions of inflammation versus effects of the complex interplay with other CVD risk factors may never be fully elucidated and for the foreseeable future, inflammation is posed to maintain its current position as both a marker and a maker of CVD, with clinical utility both for identification of patient at risk of CVD and as target for therapy to reduce CVD. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Chronic inflammatory disease; atherosclerosis; cardiovascular disease; inflammation; inflammatoryzzm321990bowel disease; periodontitis; psoriasis; rheumatoid arthritis.

Mesh:

Substances:

Year:  2018        PMID: 29318966     DOI: 10.2174/1381612824666180110102341

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  4 in total

Review 1.  Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty.

Authors:  Luigi Ferrucci; Elisa Fabbri
Journal:  Nat Rev Cardiol       Date:  2018-09       Impact factor: 32.419

Review 2.  Autoimmunity, inflammation, and dysbiosis mutually govern the transition from the preclinical to the clinical stage of rheumatoid arthritis.

Authors:  Alexander Kalinkovich; Gulzan Gabdulina; Gregory Livshits
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

Review 3.  Role of Mitophagy in Coronary Heart Disease: Targeting the Mitochondrial Dysfunction and Inflammatory Regulation.

Authors:  Mingxuan Liu; Ying Wu
Journal:  Front Cardiovasc Med       Date:  2022-02-04

4.  Association of lymphocyte-to-monocyte ratio with total coronary plaque burden in patients with coronary artery disease.

Authors:  Yueqiao Si; Jingyi Liu; Weichao Shan; Ying Zhang; Chao Han; Ruijuan Wang; Lixian Sun
Journal:  Coron Artery Dis       Date:  2020-11       Impact factor: 1.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.